Publications by authors named "Gordana Jovic"

21Publications

Marginal structural models with dose-delay joint-exposure for assessing variations to chemotherapy intensity.

Stat Methods Med Res 2019 09 19;28(9):2787-2801. Epub 2018 Jun 19.

1 Mathematical Institute Leiden University, Leiden, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0962280218780619DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728750PMC
September 2019

Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial.

Eur Urol 2018 06 4;73(6):968-976. Epub 2018 Jan 4.

Institute of Cancer Research and Royal Marsden Hospitals, Sutton and London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.12.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954168PMC
June 2018

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.

J Clin Oncol 2015 Jul 1;33(20):2279-87. Epub 2015 Jun 1.

Stefan S. Bielack, Klinikum Stuttgart-Olgahospital, Stuttgart; Mathias Werner, Helios Klinikum Emil von Behring; Per-Ulf Tunn, Helios Klinikum Berlin-Buch, Berlin; Knut Helmke, Altonaer Kinderkrankenhaus, Hamburg; Heribert Jürgens, Gabriele Calaminus, Joachim Gerss, and Trude Butterfass-Bahloul, Universitätsklinikum Münster, Münster; Peter Reichardt, Klinik für Interdisziplinäre Onkologie, Bad Saarow, Germany; Sigbjørn Smeland and Kirsten Sundby Hall, Oslo University Hospital; Kirsten Sundby Hall, Norwegian Radium Hospital, Oslo, Norway; Jeremy S. Whelan, University College London Hospitals; Gordana Jovic, Jane M. Hook, and Matthew R. Sydes, University College London; Beatrice Seddon and Maria Michelagnoli, University College Hospital, London; Bernadette Brennan, Christie Hospital and Royal Manchester Children's Hospital, Manchester; Susan Picton, Leeds University Hospital, Leeds, United Kingdom; Neyssa Marina, Stanford University Medical Center; Claudia Deffenbaugh, Lucille Salter Packard Children's Hospital, Palo Alto; Mark D. Krailo, Children's Oncology Group, Arcadia, CA; Mark Gebhardt and Allen Goorin, Dana-Farber Cancer Institute; Mark Gebhardt and Lisa A. Teot, Children's Hospital Boston, Boston, MA; Zsuzsanna Pápai, National Medical Center, Budapest, Hungary; James Meyer, Children's Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, PA; Helen Nadel, British Columbia Children's Hospital and University of British Columbia, Vancouver, British Columbia; Mark Bernstein, Dalhousie University, Halifax, Nova Scotia, Canada; R. Lor Randall, University of Utah, Salt Lake City, UT; Rajaram Nagarajan, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; G. Douglas Letson, H. Lee Moffit Cancer Center and Research Institute, Tampa, FL; Daniel Baumhoer, Universitätsspital Basel; Thomas Kühne, University Children's Hospital Basel, Basel, Switzerland; Leo Kager, St Anna's Children Hospital; Reinhard Windhager, Medica

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.0734DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486345PMC
July 2015

Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer.

J Clin Oncol 2015 Jul 17;33(19):2143-50. Epub 2015 Feb 17.

Malcolm D. Mason, Cardiff University School of Medicine, Velindre Hospital; James B.P. Barber, Velindre Hospital, Cardiff; Matthew R. Sydes, Mahesh K.B. Parmar, Gordana Jovic, Medical Research Council Clinical Trials Unit at University College London, London; Peter Kirkbride, The Clatterbridge Cancer Centre National Health Service Foundation Trust, Wirral; Richard Cowan, Christie Hospital, University of Manchester, Manchester; John Anderson, Sheffield Teaching Hospitals, National Health Service Foundation Trust, Sheffield; John Hetherington, Castle Hill Hospital, Hull; Salah El-Sharkawi, South West Wales Cancer Centre, Swansea; P.D. John Hardman, The James Cook University Hospital, Middlesbrough, United Kingdom; Wendy R. Parulekar, Andrea Hiltz, and Bingshu E. Chen, NCIC Clinical Trials Group, Queen's University; Michael Brundage, Cancer Centre of Southeastern Ontario, Kingston; Mary Gospodarowicz and Padraig Warde, University of Toronto, Princess Margaret Cancer Centre; Charles Hayter, University of Toronto, Carlo Fidani Peel Regional Cancer Center, Toronto, Ontario; Edmund C. Kostashuk, Fraser Valley Cancer Centre, Surrey; Michael McKenzie, Vancouver Cancer Centre, Vancouver, British Columbia; Jinka Sathya, Memorial University of Newfoundland, St Johns, Newfoundland and Labrador, Canada; Luis Souhami, McGill University, Montreal, Quebec, Canada; and Gregory Swanson, University of Texas Health Science Center, San Antonio, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.7510DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477786PMC
July 2015

An exact method for analysis following a two-stage phase II cancer clinical trial.

Stat Med 2010 Dec;29(30):3118-25

Institute of Medical Statistics and Biometry, University of Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/sim.3837DOI Listing
December 2010

Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer.

Int J Radiat Oncol Biol Phys 2009 Feb 10;73(2):466-72. Epub 2008 Nov 10.

Division of Medical Oncology, Department of Oncology and Hematology, University Hospital, University of Modena and Reggio Emilia, Modena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2008.04.065DOI Listing
February 2009

Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).

Clin Breast Cancer 2008 Apr;8(2):192-4

Division of Medical Oncology, Department of Oncology and Hematology, University Hospital, University of Modena and Reggio Emilia, Modena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2008.n.022DOI Listing
April 2008

Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB).

Clin Breast Cancer 2008 Feb;8(1):97-100

Division of Medical Oncology, Department of Oncology and Hematology, University Hospital, University of Modena and Reggio Emilia, Modena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2008.n.010DOI Listing
February 2008

Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.

Int J Radiat Oncol Biol Phys 2007 Aug 18;68(5):1455-61. Epub 2007 Apr 18.

Division of Medical Oncology, Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2007.02.018DOI Listing
August 2007